Volume 17 - Issue 9 - September 2004
New Products »
With so many people dealing with dry skin and nail diseases, one cannot have too many options for treatment.
That is why you may want to consider adding two new products to your armamentarium. Keralac® Lotion is a 35% urea-based moisturizer manufactured by Doak Dermatologics. Offering ingredients of vitamin E, lactic acid and zinc, Keralac Lotion can promote a favorable pH level, which can increase healing and protect against harmful bacteria, according to the company.
Available in 7-ounce and 11-ounce bottles, Keralac Lotion has a light texture and patients can spread it eas
Surgical Pearls »
As foot and ankle surgeons, we are constantly reminded that we are the ultimate champions of diabetic foot care. However, another emerging problem is chronic venous insufficiency (CVI) ulcerations. While it does not have nearly the potential impact of limb loss one may see with complications from the diabetic foot, there is an increasing incidence of CVI with the continued aging of the population.
According to current estimates, CVI affects between 0.1 and 0.3 percent of the total population in the United States. The healthcare industry spends $400 million annually on treating CVI. Unlike th
News and Trends »
Podiatrists like David G. Armstrong, DPM, know the value of research in podiatric medical schools. A Professor of Surgery, Assistant Dean and Chair for Research at Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science, Dr. Armstrong says research is part of a “triad of care” along with teaching and patient care.
To that end, the podiatric medical program of Scholl College is looking toward the future with its establishment of a new research focus. Dean Terence Albright, DPM, says the school’s merger with the Rosalind Franklin Univ
Wound Care Q&A »
Assessing and treating infected diabetic foot wounds can be challenging. Providing timely treatment is essential given the potential complications of diabetic foot infections but the rise in antibiotic resistance is a key issue to consider. With this in mind, our expert panelists discuss a variety of issues, ranging from empiric antibiotic selection and MRSA infected wounds to their approach in diagnosing osteomyelitis.
Q: What empiric antibiotics do you utilize for the infected neuropathic diabetic foot ulcer?
A: Systemic antibiotics are unnecessary unless there is evidence of os
When a patient with Charcot neuroarthropathy presents with an acutely symptomatic limb, joint or a non-healing wound, the differential diagnosis always includes infection. Bone and joint infections are naturally associated with a high degree of potential morbidity. This potential morbidity is significantly increased when there is a delay in diagnosis or when the diagnosis is missed altogether. Therefore, validating a definitive diagnosis of infection and clarifying when it involves bone is essential to providing appropriate and timely treatment.
Nuclear medicine leukocyte imaging (NMLI) allow
One-third of the 17 million patients with diabetes develop manifestations of the disease that affect their skin.1,2 The cutaneous manifestations and signs of diabetes can heighten the suspicions of the practitioner regarding the diagnosis of these skin conditions. Patients with diabetes who have peripheral sensory neuropathy and impaired circulation are at an increased risk of developing complications from skin and nail conditions like onychomycosis.3 These skin changes of the foot can lead to the formation of a diabetic foot ulcer and potentially limb-threatening infecti
- « Previous
- | Page 1 of 2 |
- Next »